Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients

AIM: To assess the benefit of rituximab with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-DA-EPOCH) regimen as a first-line treatment for patients with diffuse large B-cell lymphoma (DLBCL) presenting with unfavorable or aggressive features, and autologous s...

Descripción completa

Detalles Bibliográficos
Autores principales: Pejša, Vlatko, Prka, Željko, Lucijanić, Marko, Mitrović, Zdravko, Piršić, Mario, Jakšić, Ozren, Ajduković, Radmila, Kušec, Rajko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Medical Schools 2017
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346894/
https://www.ncbi.nlm.nih.gov/pubmed/28252874
http://dx.doi.org/10.3325/cmj.2017.58.40

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346894/
https://www.ncbi.nlm.nih.gov/pubmed/28252874
http://dx.doi.org/10.3325/cmj.2017.58.40

Ejemplares similares